Asia Pacific Peripheral Embolization Coils Market
The Asia Pacific peripheral embolization coils market was valued at US$ 138.45 million in 2023 and is expected to reach US$ 204.52 million by 2031; it is estimated to register a CAGR of 5.0% from 2023 to 2031. Expanding Range of Applications of Embolization Coils Boosts Asia Pacific Peripheral Embolization Coils Market
Companies operating in the peripheral embolization coils market constantly focus on new product launches and marketing approval, which helps them improve their sales. A few of the noteworthy developments in the peripheral embolization coils market are mentioned below. In January 2024, the National Medical Products Administration provided marketing approval for the ZYLOX Phoenix Peripheral Detachable Fibered Coil Embolization System manufactured by Zylox-Tonbridge Medical Technology Co Ltd. Peripheral vascular intervention is the most prevalent application of this embolization coil system. Embolization treatment of visceral aneurysmss, endoleak management of abdominal aortic aneurysms, hemoptysis, and arteriovenous fistula are the other important clinical applications of the system, which are internationally recognized for their safety and efficacy. In April 2022, Boston Scientific Corporation received 510(k) clearance from the US Food and Drug Administration (FDA) for the EMBOLD Fibered Detachable Coil designed to block or reduce the blood flow rate in the peripheral vasculature. The newest addition to Boston Scientific's interventional oncology portfolio was designed for use in various embolization procedures, necessarily minimally invasive treatments intended to block one or more blood vessels to obstruct or reduce blood flow. The EMBOLD Fibered Detachable Coil features a single platform consisting of three coils, making it simpler for physicians to address various patient needs and anatomies. Thus, new product developments and marketing approvals are anticipated to create opportunities for growth of the peripheral embolization coils market during the forecast period.Asia Pacific Peripheral Embolization Coils Market Overview
The Asia Pacific peripheral embolization coil market is segmented into China, India, Japan, South Korea, Australia, and Rest of Asia Pacific. Market growth in this region is ascribed to the continuously advancing healthcare infrastructure, and the significant incidence of abdominal aortic aneurysms, acute gastrointestinal bleeding (AGIB), and tumors in different European countries. According to an article published in BMC Public Health in April 2022, the disease burden of aortic aneurysms in China increased dramatically from 1990 to 2020, with greater mortality rates among men, elderly populations, and residents of western provinces. Varicose veins, a common condition, affect 30% of the Indian population, particularly women. Conditions can develop over time, resulting in complications such as bleeding, clotting, and ulceration that impact the quality of life of patients. Patients with varicose veins are highly susceptible to developing deep vein thrombosis because venous stasis and damage often result in superficial phlebitis, which can spread through perforating arteries and enter the deep venous system.
According to the National Cancer Centre of Japan, the country recorded more than 1million new tumor cases and 380,400 tumor-related deaths in 2022. Colorectal, stomach, lung, and prostate tumors are the most frequent cancers in Japan, accounting for over ~45% of all cancer cases. Prostate cancer diagnoses in Japan have increased 1.8 times in the last decade. A vast number of people are being diagnosed with cancer caused by a variety of possible risk factors, most notably population aging, and the cases of prostate cancer are surging at a rapid pace. AGIB is a common emergency condition with high morbidity and death rates. It is divided into upper gastrointestinal bleeding (UGIB) and lower gastrointestinal bleeding (LGIB), which determine the course of patient evaluation and treatment. According to the Queensland Government, in Australia, UGIB affects 50-150 individuals per 100,000 people per year, with a 6-8% fatality rate. The same source also states that there is no data is available on LGIB cases in Australia. According to an article published by NIH, in 2023, traumatic injuries ranked third among the leading causes of death in South Korea, accounting for 9.2% of the total mortality. Trauma is more common in younger people, and the cases reported in men are twice those in women. South Korea has a higher preventable in-hospital trauma fatality rate than other developed countries, which ranges from 5% to 10%.
Asia Pacific Peripheral Embolization Coils Market Revenue and Forecast to 2031 (US$ Million)
Strategic insights for the Asia Pacific Peripheral Embolization Coils provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Asia Pacific Peripheral Embolization Coils refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Asia Pacific Peripheral Embolization Coils Strategic Insights
Get more information on this report Asia Pacific Peripheral Embolization Coils Report Scope
Report Attribute
Details
Market size in 2023
US$ 138.45 Million
Market Size by 2031
US$ 204.52 Million
Global CAGR (2023 - 2031)
5.0%
Historical Data
2025-2031
Forecast period
2021-2023
Segments Covered
By Type
By Material
By Application
Regions and Countries Covered
Asia Pacific
Market leaders and key company profiles
Get more information on this report Asia Pacific Peripheral Embolization Coils Regional Insights
Get more information on this report
Asia Pacific Peripheral Embolization Coils Market Segmentation
The Asia Pacific peripheral embolization coils market is categorized into type, material, application, and country.
Based on type, the Asia Pacific peripheral embolization coils market is bifurcated into detachable coil and pushable coil. The detachable coil segment held a larger market share in 2023.
In terms of material, the Asia Pacific peripheral embolization coils market is categorized into platinum, platinum & hydrogel, and platinum tungsten alloy. The platinum segment held the largest market share in 2023.
By application, the Asia Pacific peripheral embolization coils market is segmented into bleedings & trauma, malformations, tumours, visceral aneurysm, endoleak type II, and varicose veins. The bleedings & trauma segment held the largest market share in 2023.
Based on country, the Asia Pacific peripheral embolization coils market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific peripheral embolization coils market share in 2023.
Medtronic Plc; Penumbra, Inc.; Balt; Boston Scientific Corp; Cook Medical Holdings LLC; Wallaby Medical; Spartan Micro Inc.; ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO.; LTD.; Terumo Corp; and NeuroSafe Medical Co. Ltd. are among the leading companies operating in the Asia Pacific peripheral embolization coils market.
The Asia Pacific Peripheral Embolization Coils Market is valued at US$ 138.45 Million in 2023, it is projected to reach US$ 204.52 Million by 2031.
As per our report Asia Pacific Peripheral Embolization Coils Market, the market size is valued at US$ 138.45 Million in 2023, projecting it to reach US$ 204.52 Million by 2031. This translates to a CAGR of approximately 5.0% during the forecast period.
The Asia Pacific Peripheral Embolization Coils Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Peripheral Embolization Coils Market report:
The Asia Pacific Peripheral Embolization Coils Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Peripheral Embolization Coils Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Peripheral Embolization Coils Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Peripheral Embolization Coils Market
